VIATRIS INC. O.N./ US92556V1061 /
8/29/2024 10:59:50 PM | Chg. +0.040 | Volume | Bid10:59:50 PM | Ask10:59:50 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
10.720EUR | +0.37% | - Turnover: - |
10.720Bid Size: - | 10.760Ask Size: - | 12.81 bill.EUR | - | - |
GlobeNewswire
8/7
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
GlobeNewswire
6/3
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
GlobeNewswire
5/10
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire
4/11
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...
GlobeNewswire
4/1
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...
GlobeNewswire
3/20
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Boar...
GlobeNewswire
3/8
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...
GlobeNewswire
2/28
Idorsia and Viatris enter into a significant global research and development collaboration
GlobeNewswire
2/14
ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis R...
GlobeNewswire
2/5
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...
GlobeNewswire
2/2
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
1/4
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...
GlobeNewswire
1/2
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stoc...
GlobeNewswire
11/30/2023
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
GlobeNewswire
11/30/2023
Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries ...
GlobeNewswire
11/27/2023
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)